A nonionic contrast medium was evaluated in vitro for its effects on coagula tion and complement activation in comparison to a low osmolal contrast agent. In clotting assays each contrast medium was mixed with blood and clotting parameters were analyzed by using a thromboelastographic machine. Platelet function was studied by incubating platelet-rich plasma with individual contrast medium, and the subsequent challenge of a platelet aggregating agent. Comple ment activation was assessed by the hydrolysis of C3 protein into C3c fragment in contrast medium-incubated serum. Immunoelectrophoresis was used to detect C3c protein. Both the nonionic contrast medium and the low osmolal contrast agent acted as anticoagulant and antiplatelet agents, however, results with the low osmolal contrast agent were more pronounced compared to the nonionic contrast medium. Even at nonphysiologic concentration of contrast medium, no significant conversion at C3 to C3c was seen. Since these two agents caused hypo coagulable states in vitro, it is likely that patients with thrombocytopenia, se vere liver disease and with clotting factor deficiencies may present hemostatic complications during angiographic procedures.
Get full access to this article
View all access options for this article.
References
1.
Aspelin P.: Effect of ionic and nonionic contrast media on whole blood viscosity, plasma viscosity and hematocrit in vitro. Acta Radiol Diagn19:766, 1978.
2.
Speck U. and Mützel N.: Two new classes of low osmotic contrast agents: Triiodinated cations and nonionic dimers. In: Contrast Media in Radiology, p. 335. Edited by M Amiel.Springer-Verlag, Berlin1982.
3.
Almen T.: Contrast agents design. Some aspects on the synthesis of water soluble contrast agents of low osmolarity. J Theor Biol24:215, 1969.
4.
Felder E., Pitre D. and Tirone P.: Radiopaque contrast media XLIV. Preclinical studies with a new nonionic contrast agent. Farmaco Ed Sci32:835, 1977.
5.
Belan A., Benda K., Fabian J. and Blaha J.: Advantages of a new nonionic contrast medium. The results of animal experiments. AnnlRadiol21:279, 1978.
6.
Pitre D. and Felder E.: Development, chemistry and physical properties of iopamidol and its analogues . Invest Radiol15:S301, 1980.
7.
Corsi M., Moreeti C. and Biasizzo P.: Initial clinical trials with a new nonionic contrast media, iopamidol, in urography and angiography. Radiol Med66:215, 1980.
8.
Rommel AJ, Singhui S. and Sugerman AA: Intravenous iopamidol, distribution and tolerance in normal volunteers. Invest Radiol15:S421, 1980.
9.
Dalla Palma L , Rossi M., Stacal F. and Agostini R.: Iopamidol in urography. A comparison between ionic and nonionic contrast media in patients with normal and impaired renal function. Urol Radiol4:1, 1982.
10.
Halvorsen RA, Allen S., Bates M., Dunnick NR and Thompson WM: A comparison in humans of iopamidol and diatrizoate for contrast agent enhancement during abdominal CT. Assoc. Univ. Radiol. Abstract #60 1983; 42.
11.
Almen T.: Experience from 10 years of development of water-soluble nonionic contrast media. Invest Radiol15:S-238, 1980.
12.
Lee BY, Trainor FS, Thoden NR and Kavner D.: Handbook of Noninvasive Diagnostic Techniques in Vascular Surgery. Appleton-Century-Crofts, New York1981; 266.
13.
Parvez Z., Moncada R., Fareed J. and Messmore HL: Effects of nonionic contrast media (CM) on the components of coagulation and complement systems. Invest Radiol18:279, 1983.
14.
Rao VM, Rao AK, Steiner RM, Willis J., et al: Inhibition of platelet function by radiologic contrast media . Assoc. Univ. Radiol. Abstract #63 1983; 42.
15.
Belleville J., Freyria AM, Pinet A., et al: Contrast agents used for excretory urography impair platelet function in human patients. Thromb Res28:533, 1982.
16.
Parvez Z., Moncada R., et al: Antiplatelet action of intravascular contrast media. Implications in diagnostic procedures. Invest Radiol19:208, 1983.
17.
Gonsette RE and Delmotte P.: In vivo activation of serum complement by contrast media. A clinical study. Invest Radiol15(6):S-26, 1980.
